Fournier’s gangrene at a tertiary health facility in northwestern Tanzania: a single centre experiences with 84 patients

BMC Research Notes

Samson Simbila²  Joseph B. Mabula¹  John Z. Igenge²  Phillipo L. Chalya¹ 

[1] Department of Surgery, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania;Department of Urology, Bugando Medical Centre, Mwanza, Tanzania

关键词: Tanzania;    Prognostic factors;    Management;    Predisposing factors;    Fournier’s gangrene;   

Others  :  1229972
DOI  :  10.1186/s13104-015-1493-1

 received in 2014-08-01, accepted in 2015-09-21,  发布年份 2015

【 摘 要 】

Background

Fournier’s gangrene (FG) is a rare, rapidly progressive, necrotizing fasciitis of the external genitalia and perineum, leading to soft-tissue necrosis. Despite antibiotics and aggressive debridement, the mortality rate of FG remains high. This study describes our experiences in the management of FG and identifies prognostic factors.

Methods

This was a descriptive retrospective study of patients with FG treated at Bugando Medical Centre between November 2006 and April 2014.

Results

A total of 84 patients (M:F = 41:1) were studied. The median age was 34 years (range 15–76 years). The most common predisposing factor was diabetes mellitus (16.7 %). Nine (11.3 %) patients were HIV positive. Bacterial culture results were obtained in only 46 (54.8 %) patients. Of these, 38(82.6 %) had polymicrobial bacterial growth while 8 (17.4 %) had monomicrobial bacterial growth. Escherichia coli (28.3 %) were the most frequent bacterial organism isolated. All the microorganisms isolated showed high resistance to commonly used antibiotics except for Meropenem and imipenem, which were 100 % sensitive each respectively. All patients were treated with a common approach of resuscitation, broad-spectrum antibiotics, and wide surgical excision. The median length of hospital stay (LOS) was 28 days and mortality rate was 28.6 %. Systemic inflammatory response syndrome and diabetes mellitus were significantly associated with prolonged LOS (p < 0.001), whereas advancing age (>60 years), late presentation (>48 h), systemic inflammatory response syndrome on admission, diabetes mellitus, extension of infection to the abdominal wall, FG severity score >9 and HIV infection with CD4 count <200 μl/cells) were independent predictors of mortality (p < 0.001).

Conclusion

Fournier’s gangrene remains a very severe disease with high mortality rates. Early recognition of infection associated with invasive and aggressive treatment is essential for attempting to reduce mortality rates associated with this disease in our setting.

【 授权许可】

   
2015 Chalya et al.

【 图 表 】

Fig.1.

【 参考文献 】

• [1]Corman JM, Moody JA, Aranson WL: Fournier’s gangrene in a modern surgical setting: improved survival with aggressive management. Br J Urol Int 1999, 84:85-88.
• [2]Fournier JA: Gangrene foudroyante de la verge. Med Pract 1883, 4:589-597.
• [3]Eke N: Fournier’s gangrene: a review of 1726 cases. Br J Surg 2000, 87:718-728.
• [4]Edino ST, Yakubu AA, Obidiaso A: Fournier’s gangrene in a tertiary health facility in Nigeria. Afr J Urol 2005, 11:1-5.
• [5]Yanar H, Taviloglu K, Ertekin C, Guloglu R, Zorba U, Cabioglu N, Baspinar I: Fournier’s gangrene: risk factors and strategies for management. World J Surg 2006, 30:1750-1754.
• [6]Korkut M, Içöz G, Dayangaç M, Akgün E, Yeniay L, Erdoğan O, Cal C: Outcome analysis in patients with Fournier’s gangrene: report of 45 cases. Dis Colon Rectum 2003, 46:649-652.
• [7]Villanueva-Saenz E, Martinez Hernandez-Magro P, Valdes Ovalle M, Montes Vega J, Alvarez-Tostado FJF: Experience in management of Fournier’s gangrene. Tech Coloproctol 2002, 6:5-13.
• [8]Paty R, Smith AD: Gangrene and Fournier’s gangrene. Urol Clin North Am 1992, 19:149-162.
• [9]Aghaji AE: Fournier’s gangrene. Niger J Surg Sci 2000, 10:7-11.
• [10]Jeong HJ, Park SC, Seo IY, Rim JS: Prognostic factors in Fournier gangrene. Int J Urol 2005, 12:1041-1044.
• [11]Yilmazlar T, Ozturk E, Alsoy A, Ozguc H: Necrotizing soft tissue infections: APACHE II score, dissemination, and survival. World J Surg 2007, 31:1858-1862.
• [12]Roghmann F, von Bodman C, Löppenberg B, Hinkel A, Palisaar J, Noldus J: Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU Int 2012, 110:1359-1365.
• [13]Verma S, Sayana A, Kata S, Rai S: Evaluatuion of the utility of the Fournier’s gangrene severity index in the Management of Fournier’s gangrene in North India: a multicentre retrospective Study. J Cutan Aesthet Surg 2012, 5:273-276.
• [14]Sorensen MD, Krieger JN, Rivara FP, Klein MB, Wessells H: Fournier’s gangrene: management and mortality predictors in a population based study. J Urol 2009, 182:2742-2747.
• [15]Ugwumba FO, Nnabugwu II, Ozoemena OF: Fournier’s Gangrene—analysis of management and outcome in South-Eastern Nigeria. S Afr J Surg 2012, 50:16-19.
• [16]Sorensen MD, Krieger JN, Rivara FP, Broghammer JA, Klein MB, Mack CD: Fournier’s gangrene: population based epidemiology and outcomes. J Urol 2009, 181:2120-2126.
• [17]Benjelloun EB, Souiki T, Yakla N, Ousadden A, Mazaz K, Louchi A, Kanjaa N, Taleb KA: Fournier’s gangrene: our experience with 50 patients and analysis of factors affecting mortality. World J Emerg Surg 2013, 8:13. BioMed Central Full Text
• [18]Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI: Outcome prediction in patients with Fournier’s gangrene. J Urol 1995, 154:89-92.
• [19]Ghnnam WM: Fournier’s gangrene in Mansoura Egypt: A review of 74 cases. J Postgrad Med 2008, 54:106-109.
• [20]Antonio A, Filho DC, Montovani LM: Management of Fournier’s gangrene: experience of a University Hospital of Curitiba. J Braz Coll Surg 2010, 37:435-441.
• [21]Khan I: Experience in management of Fournier’s gangrene: a review of 19 Cases. Gomal J Med Sci 2009, 7:65-67.
• [22]Malik AM, Sheikh S, Pathan R, Khan A, Sheikh U: The spectrum of presentation and management of Fournier’s gangrene-an Experience of 73 Cases. J Pak Med Assoc 2010, 60:617-619.
• [23]García A, Martín J, Vaquero A, Sánchez T, de Tomás J, Lago J, Turégano F: Fournier’s gangrene: analysis of prognostic variables in 34 patients. Eur J Trauma Emerg Surg 2011, 37:141-145.
• [24]Jarboui S, Jarraya H, Daldoul S, Zaouche A: Étude clinique et thérapeutique et analyse pronostique des gangrènes du périnée. Presse Med 2008, 37:760-766.
• [25]Dahm P, Roland FH, Vaslef SN, Moon RE, Price DT, Georgiade GS, Vieweg J: Outcome analysis in patients with primary necrotizing fasciitis of the male genitalia. Urology 2000, 56:31-35.
• [26]Ayumba BR, Magoha GA: Epidemiological aspects of Fournier’s gangrene at Kenyatta National Hospital, Nairobi. East Afr Med J. 1998, 75:586-589.
• [27]Urassa M, Isingo R, Kumogola Y, Mwidunda P, Helelwa M, Changulucha J, Mngara J, Zaba B, Calleja T, Slaymaker E: Effect of PMTCT availability on choice of ANC in Mwanza and Magu districts and its impact on HIV sentinel surveillance in Tanzania. Report of ANC surveillance Mwanza and Magu Districts; 2007.
• [28]Aji SA, Alhassan SU, Ujudud MM: Fournier’s Gangrene: experience with management of 46 cases in a tertiary institution. Open J Urol 2012, 3:109-112.
• [29]Korhonen K, Hirn M, Niinikoski J: Hyperbaric oxygen in the treatment of Fournier’s gangrene. Eur J Surg 1998, 164:251-255.
• [30]Wang C, Lau J: Hyperbaric oxygen therapy in treatment of hypoxic wounds. Hyperbaric Oxigen. 2001.